CA2327477A1 - 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists - Google Patents

4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists Download PDF

Info

Publication number: CA2327477A1
Authority: CA; Canada
Prior art keywords: alkyl; hydrogen; pharmaceutically acceptable; compound; indol
Prior art date: 1998-04-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002327477A

Other languages

English (en)

French (fr)

Inventor

James Albert Nelson

Mira Ana Kanzelberger

Richard Eric Mewshaw

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wyeth LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-13

Filing date

1999-04-12

Publication date

1999-10-21

1999-04-12 Application filed by Individual filed Critical Individual

1999-10-21 Publication of CA2327477A1 publication Critical patent/CA2327477A1/en

Status Abandoned legal-status Critical Current

Links

VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title description 24
229960003638 dopamine Drugs 0.000 title description 12
239000000556 agonist Substances 0.000 title description 11
102000007527 Autoreceptors Human genes 0.000 title description 7
108010071131 Autoreceptors Proteins 0.000 title description 7
VDOCKFSZRVQBRU-UHFFFAOYSA-N 4-amino-1-(ethylamino)-3h-indol-2-one Chemical compound C1=CC=C(N)C2=C1N(NCC)C(=O)C2 VDOCKFSZRVQBRU-UHFFFAOYSA-N 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 60
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
239000001257 hydrogen Substances 0.000 claims abstract description 16
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
229910052736 halogen Inorganic materials 0.000 claims abstract description 8
150000002367 halogens Chemical class 0.000 claims abstract description 8
150000004703 alkoxides Chemical class 0.000 claims abstract description 7
125000001624 naphthyl group Chemical group 0.000 claims abstract description 7
125000001424 substituent group Chemical group 0.000 claims abstract description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 13
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract 7
125000000217 alkyl group Chemical group 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
208000018737 Parkinson disease Diseases 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 4
BXXFMSZXDGPOOE-UHFFFAOYSA-N 4-[2-(benzylamino)ethylamino]-1,3-dihydroindol-2-one Chemical compound N1C(=O)CC2=C1C=CC=C2NCCNCC1=CC=CC=C1 BXXFMSZXDGPOOE-UHFFFAOYSA-N 0.000 claims description 3
230000002159 abnormal effect Effects 0.000 claims description 2
GSSMCAUEXVAPDF-UHFFFAOYSA-N 4-[2-[benzyl(methyl)amino]ethylamino]-1,3-dihydroindol-2-one Chemical compound C=1C=CC=2NC(=O)CC=2C=1NCCN(C)CC1=CC=CC=C1 GSSMCAUEXVAPDF-UHFFFAOYSA-N 0.000 claims 1
230000002932 anti-schizophrenic effect Effects 0.000 claims 1
230000015883 synaptic transmission, dopaminergic Effects 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
239000007787 solid Substances 0.000 description 22
125000006239 protecting group Chemical group 0.000 description 18
239000000203 mixture Substances 0.000 description 17
239000000243 solution Substances 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
238000000921 elemental analysis Methods 0.000 description 14
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
-1 such as Chemical class 0.000 description 10
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
239000007788 liquid Substances 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
239000012267 brine Substances 0.000 description 7
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000000969 carrier Substances 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
238000000746 purification Methods 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
239000002904 solvent Substances 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000003291 dopaminomimetic effect Effects 0.000 description 4
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
238000001914 filtration Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000007848 Alcoholism Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
208000000323 Tourette Syndrome Diseases 0.000 description 3
208000016620 Tourette disease Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
239000012043 crude product Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
206010013663 drug dependence Diseases 0.000 description 3
239000012458 free base Substances 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000004031 partial agonist Substances 0.000 description 3
230000001242 postsynaptic effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000000725 suspension Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101150049660 DRD2 gene Proteins 0.000 description 2
102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
230000000561 anti-psychotic effect Effects 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940052760 dopamine agonists Drugs 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
KLERUGSWEARMCQ-UHFFFAOYSA-N n-benzyl-n'-(1h-indol-4-yl)ethane-1,2-diamine Chemical compound C=1C=CC=2NC=CC=2C=1NCCNCC1=CC=CC=C1 KLERUGSWEARMCQ-UHFFFAOYSA-N 0.000 description 2
FPHMFFQPUKBKCO-UHFFFAOYSA-N n-benzyl-n-[2-[(3-chloro-1h-indol-4-yl)-(2,2,2-trifluoroacetyl)amino]ethyl]-2,2,2-trifluoroacetamide Chemical compound C=1C=CC=2NC=C(Cl)C=2C=1N(C(=O)C(F)(F)F)CCN(C(=O)C(F)(F)F)CC1=CC=CC=C1 FPHMFFQPUKBKCO-UHFFFAOYSA-N 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000010998 test method Methods 0.000 description 2
0 *N(CCI(*)I*)c1cccc(N2)c1CC2=O Chemical compound *N(CCI(*)I*)c1cccc(N2)c1CC2=O 0.000 description 1
IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
OTHYZXCZUIIJTH-UHFFFAOYSA-N 2-(benzylamino)-n-(1h-indol-4-yl)acetamide Chemical compound C=1C=CC=2NC=CC=2C=1NC(=O)CNCC1=CC=CC=C1 OTHYZXCZUIIJTH-UHFFFAOYSA-N 0.000 description 1
DIMSNKZWQDGIPX-UHFFFAOYSA-N 2-chloro-n-(1h-indol-4-yl)acetamide Chemical compound ClCC(=O)NC1=CC=CC2=C1C=CN2 DIMSNKZWQDGIPX-UHFFFAOYSA-N 0.000 description 1
LUNUNJFSHKSXGQ-UHFFFAOYSA-N 4-Aminoindole Chemical compound NC1=CC=CC2=C1C=CN2 LUNUNJFSHKSXGQ-UHFFFAOYSA-N 0.000 description 1
NLSIENBLFOGJNJ-UHFFFAOYSA-N 4-[2-(benzylamino)ethylamino]-1,3-dihydroindol-2-one;dihydrochloride Chemical compound Cl.Cl.N1C(=O)CC2=C1C=CC=C2NCCNCC1=CC=CC=C1 NLSIENBLFOGJNJ-UHFFFAOYSA-N 0.000 description 1
PWESFNSYLOJSMV-UHFFFAOYSA-N 4-[2-[benzyl(methyl)amino]ethylamino]-1,3-dihydroindol-2-one;dihydrochloride Chemical compound Cl.Cl.C=1C=CC=2NC(=O)CC=2C=1NCCN(C)CC1=CC=CC=C1 PWESFNSYLOJSMV-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
208000022497 Cocaine-Related disease Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
201000006145 cocaine dependence Diseases 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
PGEYVUHYUBVINE-UHFFFAOYSA-N n-[2-[benzyl(methyl)amino]ethyl]-2,2,2-trifluoro-n-(1h-indol-4-yl)acetamide Chemical compound C=1C=CC=2NC=CC=2C=1N(C(=O)C(F)(F)F)CCN(C)CC1=CC=CC=C1 PGEYVUHYUBVINE-UHFFFAOYSA-N 0.000 description 1
HQPDXPGCUJZTMB-UHFFFAOYSA-N n-benzyl-2,2,2-trifluoro-n-[2-[(2-oxo-1,3-dihydroindol-4-yl)-(2,2,2-trifluoroacetyl)amino]ethyl]acetamide Chemical compound C=1C=CC=2NC(=O)CC=2C=1N(C(=O)C(F)(F)F)CCN(C(=O)C(F)(F)F)CC1=CC=CC=C1 HQPDXPGCUJZTMB-UHFFFAOYSA-N 0.000 description 1
RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
SMPAPEKFGLKOIC-UHFFFAOYSA-N oxolane;hydrochloride Chemical compound Cl.C1CCOC1 SMPAPEKFGLKOIC-UHFFFAOYSA-N 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
229950001675 spiperone Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Addiction (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002327477A 1998-04-13 1999-04-12 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists Abandoned CA2327477A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5883498A	1998-04-13	1998-04-13
US09/058,834		1998-04-13
PCT/US1999/007967 WO1999052870A1 (en)	1998-04-13	1999-04-12	4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists

Publications (1)

Publication Number	Publication Date
CA2327477A1 true CA2327477A1 (en)	1999-10-21

Family

ID=22019205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002327477A Abandoned CA2327477A1 (en)	1998-04-13	1999-04-12	4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists

Country Status (8)

Country	Link
EP (1)	EP1073636A1 (de)
JP (1)	JP2002511450A (de)
CN (1)	CN1297439A (de)
AR (1)	AR014847A1 (de)
AU (1)	AU3555099A (de)
CA (1)	CA2327477A1 (de)
WO (1)	WO1999052870A1 (de)
ZA (1)	ZA992670B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7053092B2 (en)	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
AR032641A1 (es) *	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en)	2001-09-25	2014-04-22	Otsuka Pharmaceutical Co., Ltd.	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4452808A (en) *	1982-12-07	1984-06-05	Smithkline Beckman Corporation	4-Aminoalkyl-2(3H)-indolones
GB8712073D0 (en) *	1987-05-21	1987-06-24	Smith Kline French Lab	Medicament
EP0641202A1 (de) *	1992-05-18	1995-03-08	Smithkline Beecham Plc	Verwendung von indolonderivaten zur behandlung von gedaechtnisstoerungen, sexuele fehlwirkungen und morbus parkinson
ATE218548T1 (de) *	1996-08-27	2002-06-15	American Home Prod	4-aminoethoxy-indolon-derivate

1999
- 1999-04-12 ZA ZA9902670A patent/ZA992670B/xx unknown
- 1999-04-12 AU AU35550/99A patent/AU3555099A/en not_active Abandoned
- 1999-04-12 AR ARP990101678A patent/AR014847A1/es unknown
- 1999-04-12 WO PCT/US1999/007967 patent/WO1999052870A1/en not_active Ceased
- 1999-04-12 CA CA002327477A patent/CA2327477A1/en not_active Abandoned
- 1999-04-12 JP JP2000543433A patent/JP2002511450A/ja active Pending
- 1999-04-12 EP EP99917423A patent/EP1073636A1/de not_active Withdrawn
- 1999-04-12 CN CN99805030A patent/CN1297439A/zh active Pending

Also Published As

Publication number	Publication date
JP2002511450A (ja)	2002-04-16
AR014847A1 (es)	2001-03-28
AU3555099A (en)	1999-11-01
ZA992670B (en)	2000-10-12
EP1073636A1 (de)	2001-02-07
WO1999052870A1 (en)	1999-10-21
CN1297439A (zh)	2001-05-30

Legal Events

Date	Code	Title	Description
2002-04-12	FZDE	Dead

Publication	Publication Date	Title
KR910001042B1 (ko)	1991-02-21	4-아미노알킬-2(3h)-인돌론 및 이의 제조방법
EP0923548B1 (de)	2003-03-12	4-aminoethoxy-indolderivate als dopamin d2 agonisten und als 5ht1a liganden
US20030027832A1 (en)	2003-02-06	4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
EP0923551B1 (de)	2002-06-05	4-aminoethoxy-indolon-derivate
CA2327477A1 (en)	1999-10-21	4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
US5958965A (en)	1999-09-28	4-aminoethoxy indoles
US6228880B1 (en)	2001-05-08	4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
US5817690A (en)	1998-10-06	4-aminoethoxy indolone derivatives
US6127380A (en)	2000-10-03	4-aminoalkoxy-1H-benzoimidazoles
EP0923576B1 (de)	2002-11-06	4-aminoethoxy-indolonderivate als dopamin d2 agonisten
AU746717B2 (en)	2002-05-02	4-aminoalkoxy-1H-benzimidazole derivatives, their preparation and their use as dopamine autoreceptor (D2) agonists
AU722616B2 (en)	2000-08-10	5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
US5922715A (en)	1999-07-13	5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
US5760070A (en)	1998-06-02	4-Aminoethoxy indolone derivatives
US6103744A (en)	2000-08-15	4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor agonists
AU744443B2 (en)	2002-02-21	4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (D2) agonists
JPH02264780A (ja)	1990-10-29	α―アドレナリン作動性受容体拮杭剤
MXPA99007585A (en)	2000-06-01	4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, theirpreparation and their use as dopamine autoreceptor (d2) agonists
CA2278718A1 (en)	1998-08-20	4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-thiones derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists
MXPA99007587A (en)	2000-11-01	4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-thiones derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists
CA2327513A1 (en)	1999-10-14	N-aryloxyethyl-indoly-alkylamines for the treatment of depression
MXPA99007586A (en)	2000-11-01	4-aminoalkoxy-1h-benzimidazole derivatives, their preparation and their use as dopamine autoreceptor (d2
MXPA99007593A (en)	2000-11-01	5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists